Unipharma Syria is a prominent pharmaceutical company in Syria specializing in the production of high-quality pharmaceutical products. Established in 1990 as a limited family company, it operates in compliance with the Syrian Investment Law No. 10 and GMP standards set by WHO. The company's manufacturing plant, located near Damascus, covers a significant land area and is equipped for expansion to further its production capacity.
What sets Unipharma Syria apart is its dedication to quality control and assurance. The company collaborates with experts from leading international pharmaceutical firms, manufacturing products under license and direct supervision to meet the most current GMP rules and high pharmaceutical standards. This commitment has been recognized with approvals from the Syrian Ministry of Health, the Russian Federation Ministry of Health, and the National Medicinal board at Sudan Ministry of Health.
Given its strong foothold in the biotechnology, manufacturing, and pharmaceutical industries, Unipharma Syria presents an attractive investment opportunity for venture capitalists seeking to support a reputable player in the healthcare sector. With its steady growth and commitment to excellence, Unipharma Syria is poised for further success in the market.
There is no investment information
No recent news or press coverage available for Unipharma Syria.